I am researching some companies in the medical aesthetics space (INMD, CUTR, VERO, AGN, EOLS) and was wondering in this space, what multiple do companies typically trade at from a few different key metrics such as price to sales, P/E ratio, and any other metrics that you feel would be relevant to this space from a valuation perspective? Thanks.
Q: Please evaluate Novocare as a potential growth stock. Comments I have read are below and it would be great to hear if you see potential for this to rise as we get back to treating "elective" issues.
Unfortunately, the pandemic has delayed enrollment in some clinical trials. But ultimately, this is the only company with a "fourth modality" of cancer treatment beyond surgery, radiation, and chemotherapy — and with no competitors in sight.
Q: GRUB is being acquired and what I read it is at a $75/share but the stock is at $62 even after the deal was announced. Any reason why it did not run up to the take out price? Looking to see what the best exist strategy is so that the funds can be redeployed.
Q: I would to start a position in all 3 of above mentioned stocks, however, based on today,s action I am thinking I should, I love the long term prospects of all 3, and will be a long term holder. Especially the first two, I really like the exposure to the av technology, I think it’s coming sooner than most people think, and I think it will transform many industries, your general thoughts would be most appreciated
Q: Good Morning, I enjoy your site very much. I am looking for a top 8 list of U.S. Dividend Aristocrats to buy now and hold long term while taking advantage of any DRIP's. That is also paying north of a 5% dividend.
Q: Hi Peter and Ryan.
The market is a bit crazy lately, with many tech companies reaching all time high, as if the covid-19 has never happened. I think there should be good companies that are still worth to buy. I am wondering how you think about the listed three companies (e.g. CAR, EXPE, LUV).
Q: I have 8 below US stocks and would like your expert opinion on which stocks are best to hold, sell, or buy more. Does anyone has big DEBTS and how is their management. If you have to sell in which order I should sell. MSFT is about 4% and all others are only 2% of my portfolio.
Q: With apologies to the members who do not appreciate US content, I am hopeful to get your thoughts on Quidel. How would you assess its potential for capital appreciation in the next year or two? There is a Covid angle which is almost a reason not to buy in my opinion (it has to end right?) but other business opportunities as well. Thoughts on whether to buy, sell or hold and why if you can please.
Q: These are the US holdings in my RSP. All have done well except for SYK down about 8% with a limited outlook for the rest of 2020 based on the Covid pandemic. Regardless of sector weighting, what are your favorite 2 or 3 US equities for growth over the next 5 years? I'm okay with a moderate risk.
Thanks in advance,
Greg.
Q: In a recent response to a portfolio question you said you couldn't comment on over 40 stocks in the portfolio but could comment on a few of them. Of IBM you said: "IBM we consider 'meh' and there are better ideas."
My question is this: Couldn't IBM have a place in a diversified RRIF portfolio from the perspective that it provides a reliable income stream to help meet mandatory minimum withdrawals? If you have to withdraw say a minimum of 4% a year, then IBM's 5% dividend certainly helps. If you still don't like IBM in this context, what else would you suggest for a 20 year hold?